Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Decades of research indicate mitochondria from Alzheimer's disease (AD) patients differ
from those of non-AD individuals. Initial studies revealed structural differences, and …

This article describes the public health impact of Alzheimer's disease (AD), including
incidence and prevalence, mortality and morbidity, costs of care, and the overall impact on …

Background Alzheimer's disease and its complications are the leading cause of death in
adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with …

Introduction Plasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation
and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer's disease …

This report describes the public health impact of Alzheimer's disease, including incidence
and prevalence, mortality rates, costs of care, and the overall impact on caregivers and …

The function of neural circuits and networks can be controlled, in part, by modulating the
synchrony of their components' activities. Network hypersynchrony and altered oscillatory …

Accumulation of toxic protein aggregates—amyloid-β (Aβ) plaques and
hyperphosphorylated tau tangles—is the pathological hallmark of Alzheimer disease (AD) …

In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …

This article describes the public health impact of Alzheimer's disease (AD), including
incidence and prevalence, mortality rates, costs of care, and the overall impact on caregivers …